Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=380&ordering=end_effective
{ "count": 2244, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=400&ordering=end_effective", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=360&ordering=end_effective", "results": [ { "id": 1510, "title": { "de": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials", "en": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials" }, "short": "IMPPACT", "url": null, "abstract": { "de": "IMPPACT will develop an intervention planning and monitoring application for Radiofrequency Ablation (RFA) of malignant liver tumours. RFA is a minimally invasive form to treat cancer without open surgery, by placing a needle inside the malignancy and destroying it through intensive heating. Though the advantages of this approach ale obvious, the intervention is currently hard to plan, almost impossible to monitor or assess, and therefore is not the first choice for treatment. IMPPACT will develop a physiological model of the liver and simulate the intervention's result, accounting for patient specific physiological factors. Gaps in the understanding of particular aspects of the RFA treatment will be closed by multi-scale studies on cells and animals. New findings will be evaluated microscopically and transformed into macroscopic equations. The long-established bio-heat equation will be extended to incorporate multiple scales. Validation will be performed at multiple levels. Images from ongoing patient treatment will be used to cross check validity for human physiology. Final validation will be performed at macroscopic level through visual comparison of simulation and treatment results gathered in animal studies and during patient treatment. This extensive validation together with a user-centered software design approach will guarantee suitability of the solution for clinical practice. The consortium consists of two Hospitals, three Universities, one Research Institute and one industrial SME. The final project deliverables will be the patient specific intervention planning system and an augmented reality training simulator for the RFA intervention.", "en": "IMPPACT will develop an intervention planning and monitoring application for Radiofrequency Ablation (RFA) of malignant liver tumours. RFA is a minimally invasive form to treat cancer without open surgery, by placing a needle inside the malignancy and destroying it through intensive heating. Though the advantages of this approach ale obvious, the intervention is currently hard to plan, almost impossible to monitor or assess, and therefore is not the first choice for treatment. IMPPACT will develop a physiological model of the liver and simulate the intervention's result, accounting for patient specific physiological factors. Gaps in the understanding of particular aspects of the RFA treatment will be closed by multi-scale studies on cells and animals. New findings will be evaluated microscopically and transformed into macroscopic equations. The long-established bio-heat equation will be extended to incorporate multiple scales. Validation will be performed at multiple levels. Images from ongoing patient treatment will be used to cross check validity for human physiology. Final validation will be performed at macroscopic level through visual comparison of simulation and treatment results gathered in animal studies and during patient treatment. This extensive validation together with a user-centered software design approach will guarantee suitability of the solution for clinical practice. The consortium consists of two Hospitals, three Universities, one Research Institute and one industrial SME. The final project deliverables will be the patient specific intervention planning system and an augmented reality training simulator for the RFA intervention." }, "begin_planned": "2008-06-01T02:00:00+02:00", "begin_effective": "2008-09-01T02:00:00+02:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2008-04-09T17:00:52+02:00", "program": 24, "subprogram": null, "organization": 14073, "category": 10, "type": 10, "partner_function": 2, "manager": 50874, "contact": 50874, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1510-50874-10", "1510-62118-12", "1510-51955-12", "1510-51983-12" ] }, { "id": 2498, "title": { "de": "Die Rolle von Metalloproteasen und Endothelin im ersten Schwangerschaftstrimester", "en": "The role of metalloproteinases and endothelin in the first trimester of pregnancy" }, "short": "METALLPROTEINASES_ENDOTHELIN_PREGNANCY", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-07-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2011-06-16T12:49:53+02:00", "program": null, "subprogram": null, "organization": 14038, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2130, "title": { "de": "Kinder erzählen: Text- und Erzählkompetenz im Vorschulalter: eine Voraussetzung für den schulischen Erfolg.", "en": "Narratives in first language acquisition." }, "short": "TEXT- UND ERZÄHLKOMPETENZ", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-03-01T01:00:00+01:00", "begin_effective": "2010-03-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-02-24T10:55:39+01:00", "program": null, "subprogram": null, "organization": 14010, "category": 10, "type": 10, "partner_function": 2, "manager": 58883, "contact": 58883, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2130-58883-10" ] }, { "id": 2031, "title": { "de": "Genetic variants in the RAD51, BRCA1 and BRCA2 genes as predictors of radiation response and toxicity in prostate cancer patients", "en": "Genetic variants in the RAD51, BRCA1 and BRCA2 genes as predictors of radiation response and toxicity in prostate cancer patients" }, "short": "GENETIC_PROSTATE_CANCER_OeNB", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-01-11T15:12:11+01:00", "program": 79, "subprogram": null, "organization": 14060, "category": 10, "type": 10, "partner_function": 4, "manager": 50495, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2031-50495-10", "2031-50910-12" ] }, { "id": 2092, "title": { "de": "Analysis of germline polymorphisms in the VEGF/VEGFR pathway to predict colorectal cancer outcome", "en": "Analysis of germline polymorphisms in the VEGF/VEGFR pathway to predict colorectal cancer outcome" }, "short": "GERMLINE POLYMORPH VEGF/VEGFR", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2010-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-02-09T11:47:57+01:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 894 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2092-58814-12" ] }, { "id": 1329, "title": { "de": "Mapping of the bound proton fraction in the elderly brain", "en": "Mapping of the bound proton fraction in the elderly brain" }, "short": "BOUND_PROTON_ELDERLY_BRAIN_FWF07", "url": null, "abstract": { "de": "The aim of this proposal is to investigate whether the bound pool fraction as a new and quantitative MR measure allows more insight into age related brain tissue changes than other quantitative MR measures. The specific aims are:\r\n\r\n*Develop a MR pulse sequence that allows to map the bound proton fraction on high field systems (>=3T) within a clinically reasonable measurement time (<15min). The sequence should offer whole brain coverage and should overcome current limitations such as the susceptibility for motion and B1 effects.\r\n\r\n*Measure the BPF in brain tissue of a large cohort of the Ausitria Stroke Prevention Study (ASPS). This gives us the opportunity to study a representative and homogeneous group of normal elderly people without a history or signs of neuropsychiatric diseases. By using a younger control cohort, we want to investigate how the BPF changes as a function of age, sex and anatonic region including cortical structures. In addition, we want to find out how the BPF varies within WMH with different severity and how it relates to the BPF in normal appearing brain tissue and to the neurocognitive performance.\r\n\r\n*Compare the sensitivity and specificity of bound proton fraction mapping to more established measures of brain tissue changes including atrophy, diffusion weighted imaging, and magnetization transfer imaging.", "en": "The aim of this proposal is to investigate whether the bound pool fraction as a new and quantitative MR measure allows more insight into age related brain tissue changes than other quantitative MR measures. The specific aims are:\r\n\r\n*Develop a MR pulse sequence that allows to map the bound proton fraction on high field systems (>=3T) within a clinically reasonable measurement time (<15min). The sequence should offer whole brain coverage and should overcome current limitations such as the susceptibility for motion and B1 effects.\r\n\r\n*Measure the BPF in brain tissue of a large cohort of the Ausitria Stroke Prevention Study (ASPS). This gives us the opportunity to study a representative and homogeneous group of normal elderly people without a history or signs of neuropsychiatric diseases. By using a younger control cohort, we want to investigate how the BPF changes as a function of age, sex and anatonic region including cortical structures. In addition, we want to find out how the BPF varies within WMH with different severity and how it relates to the BPF in normal appearing brain tissue and to the neurocognitive performance.\r\n\r\n*Compare the sensitivity and specificity of bound proton fraction mapping to more established measures of brain tissue changes including atrophy, diffusion weighted imaging, and magnetization transfer imaging." }, "begin_planned": "2007-08-01T02:00:00+02:00", "begin_effective": "2008-01-01T01:00:00+01:00", "end_planned": "2010-07-31T02:00:00+02:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2007-07-10T14:42:36+02:00", "program": 72, "subprogram": null, "organization": 14051, "category": 10, "type": 10, "partner_function": 4, "manager": 51279, "contact": 51279, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P20103", "ethics_committee": null, "edudract_number": null, "persons": [ "1329-51279-10" ] }, { "id": 2097, "title": { "de": "Role of SPN in PP1-mediated RyR2 regulation and intracellular Ca2+ handling", "en": "Role of SPN in PP1-mediated RyR2 regulation and intracellular Ca2+ handling" }, "short": "ROLE OF SPN ", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-02-09T12:56:38+01:00", "program": null, "subprogram": null, "organization": 14083, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 894 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2090, "title": { "de": "Expression profiling in hypoxic non-small cell lung cancer", "en": "Expression profiling in hypoxic non-small cell lung cancer" }, "short": "NON-SMALL CELL LUNG CANCER ", "url": null, "abstract": { "de": "Das Bronchialkarzinom ist nach wie vor die führende Krebstodesursache weltweit. 80% sind sogenannte Nicht-kleinzellige Bronchialkarzinome (non-small cell lung cancers, NSCLC). Das Gesamtüberleben der Patienten mit NSCLC ist schlecht, trotz der derzeit vorhandenen Therapieoptionen, zum Teil wegen Resistenz gegenüber Radio- und Chemotherapie. Tumorhypoxie (verminderte Sauerstoffzufuhr im Tumor) induziert in den Tumorzellen Adaptationsvorgänge und ist zum Teil für die Therapieresistenz verantwortlich. Die genauen Mechanismen sind jedoch nicht bekannt. Unser neu etabliertes ex-vivo Modell der hypoxischen Adaptation beim NSCLC, welches auf der Verwendung von kleinsten NSCLC Fragmenten aus Operationsmaterial beruht, ist geignet, um die Vorgänge im Tumor unter hypoxischen Bedingungen zu untersuchen. Das Ziel der vorliegenden Studie ist, die Genexpressionsmuster der in Hypoxie bzw unter normalen Sauerstoffbedingungen kultivierten NSCLC Fragmente zu vergleichen. Die differenziell regulierten Gene werden dafür mittels cDNA microarrays bestimmt. Die Ergebnisse werden in nachfolgenden Einzelgen-Polymerase Kettenreaktionen validiert. Unsere Studie könnte somit das Verständnis der Pathomechanismen beim Tumorwachstum verbessern und mögliche neue Therapieoptionen beim NSCLC aufzeigen.", "en": "Lung cancer is the leading cause of cancer deaths overall in the world. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers. Overall survival is poor, in part due to resistance to chemotherapy and radiotherapy. Intratumoral hypoxia (limited oxygen supply) frequently occurs in solid tumors, such as NSCLC. Hypoxia initiates adaptive responses in tumor cells and was shown to induce chemotherapy resistance and promote aggressive tumor growth. The mechanisms of hypoxia-induced adaptive responses in solid tumors are not fully elucidated, yet. We established an ex-vivo model for hypoxic adaptation using NSCLC surgery fragments. The fragments are maintained in short-time culture in hypoxia or ambient oxygen (normoxia) without significant loss of viability or increase in apoptosis and display significant induction of carbonic anhydrase IX, a marker for tumor hypoxia, under hypoxic conditions. The aim of the current study is to analyze hypoxia-induced gene expression changes using cDNA microarrays and consecutive single gene real-time polymerase chain reaction (RT-PCR) on hypoxic vs. normoxic NSCLC fragments, in order to identify genes that are consistently induced or suppressed in hypoxia. Our study thus provides a novel approach to identify molecular pathways that are crucial for hypoxic adaptive changes in NSCLC and might represent targets for therapy." }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-02-09T11:39:13+01:00", "program": null, "subprogram": null, "organization": 14087, "category": 10, "type": 10, "partner_function": 4, "manager": 57557, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 894 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2090-57557-10" ] }, { "id": 2365, "title": { "de": "Plasmakonzentration und genetische Polymorphismen von PCSK9 in Patienten mit koronarer Herzkrankheit", "en": "Plasma concentration and polymorphisms of PCSK9 in patients with coronary artery disease " }, "short": "PCSK9", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-01-01T01:00:00+01:00", "begin_effective": "2011-01-01T01:00:00+01:00", "end_planned": "2012-01-31T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2010-12-20T12:47:35+01:00", "program": 79, "subprogram": null, "organization": 14028, "category": 10, "type": 10, "partner_function": 4, "manager": 50886, "contact": 50886, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2365-50886-10" ] }, { "id": 2504, "title": { "de": "Subtyp-spezifische, nicht kompetitive metabotrope Glutamatrezeptor-1 Antoagonisten als neuer alternativer Therapieansatz bei neuroendokrinen Tumoren", "en": "Subtype-specific, non competitive metabotropic glutamatereceptor-1 antagonists as novel alternative therapeutic option for neuroendocrine tumors" }, "short": "glutamate-receptor-1 antagonists", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-07-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-06-21T11:36:12+02:00", "program": null, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2418, "title": { "de": "Uveales Melanom: Bio-psycho-soziale Aspekte", "en": "Uveal melanoma: Bio-psyco-social aspects " }, "short": "UVEAL MELANOMA_BIO_PSYCHO_SOCIAL_ASPECTS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-06-01T02:00:00+02:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-02-17T11:06:13+01:00", "program": null, "subprogram": null, "organization": 14043, "category": 10, "type": 10, "partner_function": 4, "manager": 61522, "contact": 61522, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 938 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2418-61522-10" ] }, { "id": 2379, "title": { "de": "Die Bedeutung der Th9-Achse bei Psoriasis ", "en": "The role of Th9 in psoriasis" }, "short": "TH9_PSORIASIS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-02-01T01:00:00+01:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2012-01-31T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-01-17T10:12:57+01:00", "program": null, "subprogram": null, "organization": 14047, "category": 10, "type": 10, "partner_function": 4, "manager": 51618, "contact": 51618, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 1161 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2379-51618-10" ] }, { "id": 2382, "title": { "de": "INTEROZEPTION KARDIALER AKTIVITÄT, STRESS-REAKTIVITÄT UND ATOPISCHE DERMATITIS", "en": "CARDIAC AWARENESS, STRESS REACTIVITY AND ATOPIC DERMATITIS" }, "short": "CARDIAC AWARE STRESS REACT ATOPIC DERMAT", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-02-01T01:00:00+01:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2012-02-01T01:00:00+01:00", "end_effective": "2012-02-01T01:00:00+01:00", "assignment": "2011-01-19T15:03:26+01:00", "program": null, "subprogram": null, "organization": 29447, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2496, "title": { "de": "Einfluss mechanischer Belastung auf die Expression von Matrix Metalloproteasen in Knorpelzellen aus der kindlichen Wachstumsfuge", "en": "Influence of mechanical strain on the expression of Matrix Metalloproteases in chondrocytes from the infant growth plate" }, "short": "KINDLICHE WACHSTUMSFUGE", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-06-01T02:00:00+02:00", "begin_effective": "2011-06-01T02:00:00+02:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-06-10T12:21:53+02:00", "program": null, "subprogram": null, "organization": 14049, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2529, "title": { "de": "Untersuchung der MMP Expression in der humanen Chordomzellinie MUG-Chor 1", "en": "MMP Expression Analysis on the Human Chordoma Cell Line MUG-Chor 1" }, "short": "MMP EXPRESSION ANALYSIS_CHORDOMA CELL", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-06-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2011-10-01T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-07-14T11:48:32+02:00", "program": null, "subprogram": null, "organization": 14052, "category": 10, "type": 10, "partner_function": 4, "manager": 50696, "contact": 50696, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2529-50696-10" ] }, { "id": 1716, "title": { "de": "Nano-Health: Nano-structured materials for drug targeting, release and imaging", "en": "Nano-Health: Nano-structured materials for drug targeting, release and imaging" }, "short": "NANO-HEALTH", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-01-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-14T14:15:30+01:00", "program": null, "subprogram": "Nano-Initiative", "organization": 28392, "category": 10, "type": 10, "partner_function": 2, "manager": 54033, "contact": null, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1716-54033-10" ] }, { "id": 1732, "title": { "de": "Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]", "en": "Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates" }, "short": "Oxygenierung", "url": null, "abstract": { "de": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.", "en": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-19T12:54:11+01:00", "program": 79, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": 50907, "contact": 50907, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1732-50907-10" ] }, { "id": 2414, "title": { "de": "Rolle des enterischen Nervensystems (ENS) auf die Chemotaxis von Leukozyten in der Entzuendung", "en": "Chemoattraction of leukocytes by the enteric nervous system (ENS) during inflammation" }, "short": "CHEMOATTR_LEUKOCYTES_ENS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-11-01T01:00:00+01:00", "begin_effective": "2011-03-01T01:00:00+01:00", "end_planned": "2011-10-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-02-17T09:32:46+01:00", "program": null, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 56687, "contact": 56687, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 530 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2414-56687-10" ] }, { "id": 1820, "title": { "de": "NANO-AS: Nano-Tox-Verlängerung", "en": "NANO-AS: Nano-Tox-Verlängerung" }, "short": "NANO-AS", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T12:36:34+02:00", "program": null, "subprogram": "Nano-Health", "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1819, "title": { "de": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo", "en": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo" }, "short": "Nano-Health: 4D Imaging of Stem Cells", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T11:50:29+02:00", "program": null, "subprogram": "Nano-Health", "organization": 14082, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1819-50747-12" ] } ] }